John McGreal, OD
Optometrist · Saint Louis, MONPI 1689661886
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $119,111 of the $126,350 with a category attached, or 94.3%. ABB Con-cise Optical Group LLC accounts for 93.4% of it on its own, with 22 other manufacturers making up the rest. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $775.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ABB Con-cise Optical Group LLC$118K
- Shire North American Group Inc$3K
- Alimera Sciences, Inc.$815
- Kala Pharmaceuticals, Inc.$804
- AbbVie$736
- Bausch & Lomb Americas Inc.$558
- plus $3K from 17 others
What the payments were for
- Consulting fees$119,11194%
- Speaking & faculty fees$2,0702%
- Travel & lodging$2650%
- Food & beverage$4,9044%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ABB Con-cise Optical Group LLC | 20 | $118,027 |
| Shire North American Group Inc | 9 | $2,840 |
| Alimera Sciences, Inc. | 23 | $815 |
| Kala Pharmaceuticals, Inc. | 6 | $804 |
| AbbVie(2 entities) | 20 | $736 |
| Bausch & Lomb Americas Inc. | 13 | $558 |
| Astellas Pharma US Inc | 10 | $499 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $339 |
| Mallinckrodt Hospital Products Inc. | 8 | $296 |
| Apellis Pharmaceuticals, Inc. | 7 | $279 |
| Eyevance Pharmaceuticals LLC | 6 | $200 |
| Novartis | 4 | $158 |
| Regeneron Healthcare Solutions, Inc. | 7 | $146 |
| Amgen | 1 | $125 |
| Tarsus Pharmaceuticals, Inc. | 1 | $121 |
| Genentech USA, Inc. | 3 | $90 |
| Sight Sciences, Inc. | 1 | $78 |
| Biogen | 3 | $55 |
| Harrow Eye, LLC | 2 | $48 |
| Alcon | 2 | $41 |
| Eyepoint US, Inc. | 2 | $39 |
| Glaukos Corporation | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$126,350 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 18 | $19,624 |
| LumiganBimatoprost | 24 | $13,649 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $4,147 |
| Latanoprost | 214 | $1,762 |
| Timolol Maleate | 66 | $1,313 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 15 | $734 |
| Prednisolone Acetate | 18 | $495 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $478 |
| Ketorolac Tromethamine | 12 | $104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $736 | $33,27342 claims |
| AlconSimbrinza | $41 | $4,14715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Saint Louis
- Ariel CerenzieSaint Louis$76K
- Paul LuongSaint Louis$44K
- Robert EnsleySaint Louis$38K
- Andrew RoyerSaint Louis$23K
- Robert BrusattiSaint Louis$20K
- Edward BennettSaint Louis$13K
- Craig SorceSaint Louis$8K
- Julie DekinderSaint Louis$8K
- Erin SullivanSaint Louis$6K
- Kathryn NoonanSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.